Spyre Therapeutics Inc.
SYRE | NASDAQ
$91.22
-$0.81 (-0.88%)
Sep 22, 2026, 11:59 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 886K | 2.33M | 18.74M | n/a |
Cost of Revenue | 171.65M | n/a | n/a | n/a | n/a | 1.62M |
Gross Profit | -171.65M | n/a | 886K | 2.33M | 18.74M | -1.62M |
Operating Income | -209.56M | -208.57M | -242.3M | -84.78M | -65.65M | -81.48M |
Interest Income | 24.89M | 21.31M | 6.15M | 837K | 111K | 593K |
Pretax Income | -155.22M | -207.97M | -338.82M | -83.95M | -65.66M | -80.89M |
Net Income | -155.2M | -208.02M | -338.79M | -83.82M | -65.8M | -80.89M |
Selling & General & Admin | 47.91M | 45.78M | 39.95M | 28.53M | 27.32M | 20.22M |
Research & Development | 171.65M | 162.79M | 89.5M | 58.58M | 57.07M | 59.64M |
Other Expenses | -181.65M | n/a | 113.74M | n/a | n/a | n/a |
Operating Expenses | 37.91M | 208.57M | 243.19M | 87.11M | 84.39M | 79.86M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 209.56M | 208.57M | 243.19M | 87.11M | 84.39M | 81.48M |
Income Tax Expense | -15K | 51K | -26K | -136K | 141K | n/a |
Shares Outstanding (Basic) | 64.06M | 47.03M | 6.9M | 3.37M | 2.63M | 2.13M |
Shares Outstanding (Diluted) | 64.06M | 47.03M | 6.9M | 3.37M | 2.63M | 2.13M |
EPS (Basic) | -1.98 | -3.18 | -46.15 | -24.86 | -25.02 | -37.89 |
EPS (Diluted) | -1.98 | -3.18 | -46.15 | -24.86 | -25.02 | -37.89 |
EBITDA | -209.56M | -207.97M | -127.6M | -81.99M | -64.08M | -79.27M |
EBIT | -219.56M | -207.97M | -128.56M | -83.95M | -65.66M | -80.89M |
Depreciation & Amortization | 10M | n/a | 964K | 1.96M | 1.58M | 1.62M |
Add to Watchlist
Select watchlists to add or remove SYRE